Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
amyotrophic lateral sclerosis
Biotech
MaaT posts 18-month data showing 'clear OS advantage' in aGvHD
The microbiome biotech has touted long-term data as proof it’s on track to launch the drug in acute graft-versus-host disease in two years’ time.
James Waldron
Apr 15, 2024 7:05am
After knock back, BrainStorm aligns with FDA on ph. 3 ALS trial
Apr 9, 2024 7:51am
ProJenX ALS drug gets back on the map after partial FDA hold
Mar 29, 2024 10:44am
Ferrer offers $122M biobucks for ex-US license to Verge ALS drug
Mar 25, 2024 8:16am
Seelos' sugar therapy fails to improve ALS severity in ph. 2/3
Mar 19, 2024 10:00am
Amid pivot, Denali Therapeutics sends staff packing
Feb 26, 2024 12:22pm